- Home
- GENK vs GRCE Comparison
GENK vs GRCE Comparison
Compare GENK & GRCE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GENK
- GRCE
- Stock Information
- Founded
- GENK 2011
- GRCE 2002
- Country
- GENK United States
- GRCE United States
- Employees
- GENK N/A
- GRCE N/A
- Industry
- GENK Restaurants
- GRCE
- Sector
- GENK Consumer Discretionary
- GRCE
- Exchange
- GENK Nasdaq
- GRCE NYSE
- Market Cap
- GENK 20.4M
- GRCE 42.1M
- IPO Year
- GENK 2023
- GRCE N/A
- Fundamental
- Price
- GENK $3.78
- GRCE $3.32
- Analyst Decision
- GENK Strong Buy
- GRCE Strong Buy
- Analyst Count
- GENK 2
- GRCE 1
- Target Price
- GENK $10.00
- GRCE $12.00
- AVG Volume (30 Days)
- GENK 45.5K
- GRCE 59.2K
- Earning Date
- GENK 07-30-2025
- GRCE 08-15-2025
- Dividend Yield
- GENK 0.78%
- GRCE N/A
- EPS Growth
- GENK N/A
- GRCE N/A
- EPS
- GENK N/A
- GRCE N/A
- Revenue
- GENK $214,957,000.00
- GRCE N/A
- Revenue This Year
- GENK $17.79
- GRCE N/A
- Revenue Next Year
- GENK $15.87
- GRCE N/A
- P/E Ratio
- GENK N/A
- GRCE N/A
- Revenue Growth
- GENK 14.40
- GRCE N/A
- 52 Week Low
- GENK $3.16
- GRCE $1.75
- 52 Week High
- GENK $10.33
- GRCE $4.97
- Technical
- Relative Strength Index (RSI)
- GENK 45.80
- GRCE N/A
- Support Level
- GENK $3.72
- GRCE N/A
- Resistance Level
- GENK $3.98
- GRCE N/A
- Average True Range (ATR)
- GENK 0.19
- GRCE 0.00
- MACD
- GENK 0.01
- GRCE 0.00
- Stochastic Oscillator
- GENK 49.12
- GRCE 0.00
About GENK GEN Restaurant Group Inc.
GEN Restaurant Group Inc operates an Asian casual dining restaurant chain, offering an extensive menu of traditional Korean and Korean-American food, including high-quality meats, poultry, seafood, and mixed vegetables. It operates 43 Gen Korean BBQ restaurants in the United States.
About GRCE GRACE THERAPEUTICS INC
Grace Therapeutics Inc is a late-stage specialty pharma company with drug delivery technologies and drug candidates addressing rare and orphan diseases. The company's lead drug candidate, GTx-104, is a novel injectable formulation of nimodipine for the treatment of a rare disease, aneurysmal subarachnoid hemorrhage.